{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:17:10Z","timestamp":1740176230916,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s41030-024-00267-x","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T06:01:40Z","timestamp":1722232900000},"page":"331-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01366209","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-4988","authenticated-orcid":false,"given":"Tejaswini","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-9029","authenticated-orcid":false,"given":"Chad A.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-5619","authenticated-orcid":false,"given":"Sachin","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-1943","authenticated-orcid":false,"given":"Katerina","family":"Samara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-6390","authenticated-orcid":false,"given":"Elana J.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"267_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.rmed.2016.01.019","volume":"113","author":"T Bahmer","year":"2016","unstructured":"Bahmer T, Romagnoli M, Girelli F, Claussen M, Rabe KF. The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD)\u2013a practical approach for the pulmonologist. Respir Med. 2016;113:80\u201392.","journal-title":"Respir Med"},{"key":"267_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976\u201387.","journal-title":"Eur Respir J"},{"key":"267_CR3","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"key":"267_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2018","volume":"27","author":"V Cottin","year":"2018","unstructured":"Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076.","journal-title":"Eur Respir Rev"},{"key":"267_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0109-2019","volume":"28","author":"V Cottin","year":"2019","unstructured":"Cottin V. Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases. Eur Respir Rev. 2019;28:190109.","journal-title":"Eur Respir Rev"},{"key":"267_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.rmed.2012.10.018","volume":"107","author":"JS Lee","year":"2013","unstructured":"Lee JS, Kim EJ, Lynch KL, et al. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013;107:249\u201355.","journal-title":"Respir Med"},{"issue":"Suppl 63","key":"267_CR7","volume":"54","author":"D Kalafatis","year":"2019","unstructured":"Kalafatis D, Pesonen I, Carlson L, Ferrara G, Sk\u00f6ld M. Autoantibodies in patients with idiopathic pulmonary fibrosis. Eur Respir. 2019;54(Suppl 63): PA4713.","journal-title":"Eur Respir"},{"key":"267_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094775","volume":"9","author":"M Kono","year":"2014","unstructured":"Kono M, Nakamura Y, Enomoto N, et al. Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS ONE. 2014;9:e94775.","journal-title":"PLoS ONE"},{"key":"267_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.rmed.2019.07.001","volume":"155","author":"B Ghang","year":"2019","unstructured":"Ghang B, Lee J, Kwon OC, et al. Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis. Respir Med. 2019;155:43\u20138.","journal-title":"Respir Med"},{"key":"267_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/RHU.0000000000001847","volume":"28","author":"N Jiwrajka","year":"2022","unstructured":"Jiwrajka N, Loizidis G, Patterson KC, et al. Identification and prognosis of patients with interstitial pneumonia with autoimmune features. J Clin Rheumatol. 2022;28:257\u201364.","journal-title":"J Clin Rheumatol"},{"key":"267_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083\u201392.","journal-title":"N Engl J Med"},{"key":"267_CR12","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/art.1780400909","volume":"40","author":"EM Tan","year":"1997","unstructured":"Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in \u201chealthy\u201d individuals. Arthritis Rheum. 1997;40:1601\u201311.","journal-title":"Arthritis Rheum"},{"key":"267_CR13","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3899\/jrheum.190933","volume":"47","author":"SJ Naides","year":"2020","unstructured":"Naides SJ, Genzen JR, Abel G, Bashleben C, Ansari MQ. Antinuclear antibodies testing method variability: a survey of participants in the College of American Pathologists\u2019 Proficiency Testing Program. J Rheumatol. 2020;47:1768\u201373.","journal-title":"J Rheumatol"},{"key":"267_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.rmed.2019.05.019","volume":"153","author":"GC Goobie","year":"2019","unstructured":"Goobie GC, Ford-Sahibzada CA, Fritzler MJ, Johannson KA, Fell CD. Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis. Respir Med. 2019;153:85\u201390.","journal-title":"Respir Med"},{"key":"267_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12890-021-01516-4","volume":"21","author":"MJ Song","year":"2021","unstructured":"Song MJ, Lee SH, Jung JY, et al. Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study. BMC Pulm Med. 2021;21:145.","journal-title":"BMC Pulm Med"},{"key":"267_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.mayocp.2013.11.018","volume":"89","author":"T Moua","year":"2014","unstructured":"Moua T, Maldonado F, Decker PA, Daniels CE, Ryu JH. Frequency and implication of autoimmune serologies in idiopathic pulmonary fibrosis. Mayo Clin Proc. 2014;89:319\u201326.","journal-title":"Mayo Clin Proc"},{"key":"267_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027849","volume":"9","author":"H Kamiya","year":"2019","unstructured":"Kamiya H, Panlaqui OM. Systematic review and meta-analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis. BMJ Open. 2019;9:e027849.","journal-title":"BMJ Open"},{"key":"267_CR18","doi-asserted-by":"crossref","unstructured":"Newton C, Kulkarni T, Scholand MB, et al. Autoantibody positivity in idiopathic pulmonary fibrosis: outcomes from the Pulmonary Fibrosis Foundation Patient Registry. Poster PA2893. Presented at: European Respiratory Society International Congress; 9\u201313 September 2023; Milan, Italy.","DOI":"10.1183\/13993003.congress-2023.PA2893"},{"key":"267_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.06.006","volume":"105","author":"HCS Meier","year":"2019","unstructured":"Meier HCS, Parks CG, Liu HB, et al. Cellular aging over 13 years associated with incident antinuclear antibody positivity in the Baltimore Longitudinal Study of Aging. J Autoimmun. 2019;105:102295.","journal-title":"J Autoimmun"},{"key":"267_CR20","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1002\/art.34380","volume":"64","author":"M Satoh","year":"2012","unstructured":"Satoh M, Chan EKL, Ho LA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64:2319\u201327.","journal-title":"Arthritis Rheum"},{"key":"267_CR21","doi-asserted-by":"publisher","first-page":"14532","DOI":"10.1038\/ncomms14532","volume":"8","author":"MJ Schafer","year":"2017","unstructured":"Schafer MJ, White TA, Iijima K, et al. Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. 2017;8:14532.","journal-title":"Nat Commun"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00267-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-024-00267-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-024-00267-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:51:54Z","timestamp":1724410314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-024-00267-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1007\/s41030-024-00267-x","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"type":"print","value":"2364-1754"},{"type":"electronic","value":"2364-1746"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tejaswini Kulkarni reports consultancy and speaker fees from Boehringer Ingelheim and consultancy fees from Aileron Therapeutics, PureTech LYT-100 Inc., United Therapeutics Corporation and Veracyte. Chad A. Newton reports consultancy fees from Boehringer Ingelheim. Dr. Newton is supported by the National Heart, Lung, and Blood Institute (K23 HL148498). Sachin Gupta is an employee of Genentech, Inc. Katerina Samara is an employee of F. Hoffmann-La Roche, Ltd. Elana J. Bernstein reports grants, consultancy fees and support for meeting attendance from Boehringer Ingelheim. Dr. Bernstein is also supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number K23 AR075112), the National Heart, Lung, and Blood Institute (grant number R01 HL164758), and the Department of Defence (grant number W81XWH2210163).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The ASCEND trial was conducted in compliance with Good Clinical Practice as described in FDA regulations and the 1996 International Council for Harmonisation document, in consistence with the principles stated in the Declaration of Helsinki. The protocol for the ASCEND trial was approved by the institutional review board or ethics committee at each participating centre and all patients provided written informed consent for participation in the trial. No prospective data were collected during this post-hoc analysis; therefore, ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}